This report summarises what Blossom’s database shows about psychedelic treatments for anxiety disorders, and what it does not show. The short version is a useful corrective to the hype: despite anxiety being the most common mental health problem in the world, the rigorous evidence for psychedelics in primary anxiety disorders is thin, and it rests mostly on one compound. LSD, in the form of Definium Therapeutics’ (MindMed) MM120, has a positive Phase 2b trial in generalised anxiety disorder and is in Phase 3. Almost everything else either belongs to a different problem (anxiety in life-threatening illness) or is early and uncontrolled.
A note before the evidence
This page is a research summary, not medical advice, and nothing here is a treatment recommendation. No psychedelic is approved for any anxiety disorder; the most advanced, LSD for generalised anxiety, is still in Phase 3 trials. Anxiety disorders are common and treatable with established therapies, and decisions about treatment belong with a qualified clinician.
Two scoping points matter a great deal here. First, Blossom tracks 772 papers and 110 trials under this topic, and those counts appear on the page, but the tag is unusually leaky: most of it is anxiety in the context of cancer and palliative care, or anxiety measured as a secondary outcome in depression, PTSD and OCD trials. The genuinely primary-anxiety core is small. Second, we deliberately scope this page to primary anxiety disorders (generalised anxiety, social anxiety, panic, phobia) and cover anxiety in life-threatening illness separately on our palliative page, because the latter is a distinct problem of existential distress. Read the counts as database coverage, not as a tally of anxiety-disorder treatments.
What anxiety disorders are, and why the bar is different
Anxiety disorders involve excessive, persistent fear and worry, and as a group they are the most common mental disorders worldwide, affecting around 301 million people[1]WHO, mental disorders fact sheet. Unlike treatment-resistant depression, they already have effective first-line treatments (CBT, SSRIs and SNRIs) that work for many people. That changes the bar: a new treatment has to improve on options that are genuinely useful, and the clearest unmet need is the minority who do not respond or who relapse. It is in that space that the psychedelic programmes are positioned.
LSD (MM120): the only advanced primary-anxiety programme
The single most important result on this page is from LSD. In a Phase 2b trial of 198 adults with generalised anxiety disorder, a single dose of MM120 reduced Hamilton Anxiety (HAM-A) scores by 5.0 points at 100 µg and 6.0 points at 200 µg more than placebo at four weeks[2]JAMA, MM120 (LSD) Phase 2b in GAD (2025), with benefit reported through twelve weeks from one dose. For a condition where treatments are taken daily, a durable single-dose effect would be a meaningful change.
That trial earned FDA Breakthrough Therapy designation and launched two Phase 3 trials, Voyage and Panorama, with readouts expected in 2026[3]Psychiatric Times, MM120 Breakthrough Therapy + Phase 3 (2024). It is genuinely the furthest any psychedelic has advanced in a primary anxiety disorder, and it is why this page treats LSD, not the more famous psilocybin, as the front-runner here.
The dose and blinding question
The same Phase 2b data contain the main caveats. The two lower doses (25 µg and 50 µg) did not separate from placebo[2]JAMA, MM120 (LSD) Phase 2b in GAD (2025), so the effect is dose-dependent and concentrated at doses that produce a clear psychedelic experience. And that is the problem: almost everyone on an active therapeutic dose noticed perceptual effects, against about one in ten on placebo, which makes genuine blinding very hard. Participants who can tell they received the drug may improve partly because they expect to. The Panorama Phase 3 trial was designed in part to probe exactly this, which is an encouraging sign that the developers are taking the criticism seriously rather than ignoring it.
Psilocybin: strong in cancer distress, thin for generalised anxiety
Psilocybin is where the scoping really bites. Its most impressive anxiety results come from people with life-threatening illness. Landmark 2016 trials in cancer patients found that a single high dose produced substantial reductions in anxiety and depression that were sustained at six months[4]J. Psychopharmacology, Griffiths cancer trial (2016), a finding replicated in a parallel trial[5]J. Psychopharmacology, Ross cancer trial (2016) and reinforced by a 2025 placebo-controlled palliative-care trial reporting a large, durable reduction in state anxiety[6]Gen. Hospital Psychiatry, life-threatening illness Phase 2b (2025). This is real and important, but it is about existential distress at the end of life, which we cover on our palliative page, not about generalised or social anxiety.
For primary anxiety disorders, psilocybin is early. Dedicated generalised-anxiety trials are only now recruiting, and the anxiety improvements seen in other populations often turn out to be downstream of depression: in veterans with treatment-resistant depression, anxiety scores fell by more than half but the change lost significance once depression improvement was accounted for[7]J. Affective Disorders, veterans psilocybin anxiety (2026). There is a promising signal in OCD, an anxiety-spectrum condition, where a small randomised trial reported 73% responders and 40% remission[8]J. Psychopharmacology, psilocybin OCD RCT (2026), but the sample was just fifteen people. The honest summary is that psilocybin’s reputation in anxiety rests largely on cancer work that does not transfer automatically to primary anxiety.
MDMA for social anxiety: a large signal, a weak design
Social anxiety disorder is a natural target for MDMA, which reduces fear and increases social ease. The main recent study is an open-label, waitlist-controlled trial in 20 adults with social anxiety that reported a very large improvement (Hedges’ g of 2.8) with no serious adverse events[9]MDMA-AT for social anxiety disorder, open-label (2026), extending an earlier pilot in autistic adults. The effect size is striking, but the design is weak: open-label with a waitlist rather than an active placebo, so the result cannot be separated from expectancy. It is a reason to run a proper trial, not yet a reason to believe MDMA treats social anxiety.
Ketamine and the secondary-outcome problem
Ketamine acts within hours and clearly has rapid anxiolytic properties, but its evidence in primary anxiety disorders is thin. Most of the data comes from anxiety measured as a secondary outcome in depression trials, not from dedicated anxiety studies, and the benefit is short-lived without repeated dosing. For anxiety, ketamine is best understood as a fast option for severe or refractory cases rather than an established treatment, and like the others it is not approved for any anxiety disorder.
The expectancy problem, and whether it is really anxiety
Two methodological issues run through all of this. The first is expectancy and unblinding, which is not just a worry but a measured effect: a 2026 meta-analysis found a real but modest anxiety benefit (standardised mean difference of -0.66) and, crucially, that control groups in psychedelic trials improve substantially[10]European Psychiatry, response meta-analysis (2026), the signature of strong non-specific effects. The second is conceptual: anxiety and depression travel together, and in several studies the anxiety benefit disappears once depression improvement is accounted for. So a fair reading has to ask, for each result, whether a psychedelic is treating anxiety itself or lifting a low mood that the anxiety was riding on.
Who is developing what
The commercial landscape for primary anxiety is unusually concentrated. Definium Therapeutics’ MM120 is the only psychedelic with a positive Phase 2b and Breakthrough Therapy designation in generalised anxiety disorder[3]Psychiatric Times, MM120 Breakthrough Therapy + Phase 3 (2024), and it is in two Phase 3 trials. Behind it, psilocybin formulations and Cybin’s DMT-analog CYB004 are in earlier generalised-anxiety studies, while a large amount of "anxiety" activity actually sits in cancer and palliative care. A major 2026 review placed anxiety in life-threatening illness among the emerging indications while reserving the strongest evidence for depression and PTSD[11]BMJ state-of-the-art review (2026), which is a fair description of where primary anxiety sits: promising, concentrated, and not yet proven.
Reading this honestly
So where do anxiety disorders sit? More cautiously than the volume of coverage implies. Anxiety is the most common mental health condition in the world, but for primary anxiety disorders the psychedelic evidence is thin and rests heavily on a single LSD programme that is still in Phase 3. Psilocybin’s strongest anxiety results are really about end-of-life distress; MDMA’s social-anxiety data is one small open-label trial; ketamine’s anxiety evidence is mostly secondary to depression. None of this means psychedelics will not help with anxiety; the MM120 result is real and the Phase 3 trials are well-designed. It means that, for now, the honest verdict is "promising and unproven", with the next two years of readouts likely to settle which way it goes.